Scarica l'app Stockscreener
2.11
10.21%
-0.24
Precedente Chiudi:
$2.35
Aprire:
$2.24
Volume 24 ore:
156.40K
Relative Volume:
0.15
Capitalizzazione di mercato:
$86.26M
Reddito:
-
Utile/perdita netta:
$-82.60M
Rapporto P/E:
-1.0243
EPS:
-2.06
Flusso di cassa netto:
$-48.61M
1 W Prestazione:
-10.21%
1M Prestazione:
-22.14%
6M Prestazione:
-42.51%
1 anno Prestazione:
-27.24%
Intervallo 1D:
$2.06
$2.315
Intervallo di 1 settimana:
$2.06
$2.545
Portata 52W:
$1.49
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Nome
Vigil Neuroscience Inc
Settore
Industria
Telefono
857-254-4445
Indirizzo
100 FORGE ROAD, WATERTOWN
Confronta VIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
2.11 | 86.26M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-04 | Iniziato | William Blair | Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2022-09-16 | Iniziato | Wedbush | Outperform |
| 2022-08-29 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Iniziato | Jefferies | Buy |
| 2022-02-01 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Iniziato | Stifel | Buy |
Mostra tutto
Vigil Neuroscience Inc Borsa (VIGL) Ultime notizie
Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com South Africa
Stifel maintains Buy on Vigil Neuroscience, target at $11 - Investing.com India
Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com UK
Vigil Neuroscience, Inc. SEC 10-K Report - TradingView
Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq
Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq
Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire
Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan
SPY ETF News, 3/13/2025 - The Globe and Mail
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire
Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely? - Yahoo Finance
Best Stock to Buy Right Now: Dutch Bros vs. Starbucks - The Globe and Mail
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6% - Defense World
Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Insider Monkey
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire
What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat
abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan
VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily
Are Vigil Neuroscience Inc’shares a good deal? - US Post News
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan
Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World
Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN
Guggenheim Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Vigil Neuroscience's (VIGL) Buy Rating Reiterated at Guggenheim - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat
Vigil moves into Phase II with Alzheimer's pill - The Pharma Letter
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update) - MSN
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial By Investing.com - Investing.com South Africa
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments - Seeking Alpha
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - AOL
Vigil Neuroscience stock up on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience stock gains on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience Announces Positive Phase 1 Trial Results - TipRanks
Vigil Neuroscience shares rise on positive Alzheimer's trial data By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Vigil Neuroscience Reports Positive Data from its Phase 1 - GlobeNewswire
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for - The Bakersfield Californian
Vigil's Alzheimer's Drug Shows Promising Phase 1 Results with 50% Brain Biomarker Reduction - StockTitan
Vigil Neuroscience, Inc. Reports Positive Data from its Phase 1 Clinical Trial Evaluating Vv-3927 for the Potential Treatment of Alzheimer's Disease - Marketscreener.com
Suncor Energy: AI-Powered Stock Analysis on Jefferies Valuation Update - The Globe and Mail
Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register
Vigil Neuroscience Inc Azioni (VIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):